Endocannabinoid system protects against cryptogenic seizures

Pharmacological Reports

Volumn 63, Issue 1, 2011, Pages 165-168

  Van Rijn, Clementina M ^a   Perescis, Martin F J ^a,b   Vinogradova, Lyudmila ^a,c   Van Luijtelaar, Gilles ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b University of Applied Sciences   (Netherlands)

^c INSTITUTE OF HIGHER NERVOUS ACTIVITY AND NEUROPHYSIOLOGY   (Russian Federation)

Author keywords

Cannabis; Cryptogenic seizures; Endocannabinoid system; Epilepsy; Rimonabant

Indexed keywords

ENDOCANNABINOID; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; CRYPTOGENIC SEIZURE; ELECTROENCEPHALOGRAM; FEMALE; NEUROPROTECTION; NONHUMAN; RAT; SEIZURE;

EID: 79953182386     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(11)70411-x     Document Type: Article

References (31)

1. Alger BE: Not too excited? Thank your endocannabinoids. Neuron, 2006, 51, 393-395.
2. Bernard C, Milh M, Morozov YM, Ben-Ari Y, Freund TF, Gozlan H: Altering cannabinoid signaling during development disrupts neuronal activity. Proc Natl Acad Sci USA, 2005, 102, 9388-9393.
3. Corcoran ME, McCaughran JA, Wada JA: Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled rats. Epilepsia, 1978, 19, 47-55.
4. Court A, Breteler MMB, Meinardi H, Hauser WA, Hofman A: Prevalence of epilepsy in the elderly: The Rotterdam study. Epilepsia, 1996, 37, 141-147.
5. Deshpande LS, Sombati S, Blair RE, Carter DS, Martin BR, DeLorenzo RJ: Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett, 2006, 411, 11-16.
6. Di Marzo V: Targeting the endocannabinoid system; to enhance or reduce. Nat Rev Drug Discov, 2008, 7, 438-455.
7. Le Foll B, Gorelick DA, Goldberg SR: The future of endocannabinoid- oriented clinical research after CB1 antagonists. Psychopharmacology, 2009, 205, 171-174.
8. Hampson AJ, Grimaldi M, Axelrod J, Wink D: Cannabidiol and (-)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA, 1998, 95, 8268-8273.
9. Hansen HH, Azcoitia I, Pons S, Romero J, García-Segura LM, Ramos JA. Hansen HS, Fernández-Ruiz J: Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem, 2002, 82, 154-158.
10. Hauser WA, Annegers JF, Kurland LT: Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia, 1991, 32, 429-445.
11. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ acomplia/H-666-en6.pdf (2006).
12. http://www.emea.europa.eu/humandocs/PDFs/EPAR/zimulti/ 3956009en.pdf (Jan. 2009).
13. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4306b1-fda-backgrounder.pdf (June 2007).
14. Jetter GM, Cavazos JE: Epilepsy in the elderly. Semin Neurol, 2008, 28, 336-341.
15. Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, Bahr BA: Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther, 2007, 322, 1059-1066.
16. Katona I, Freund TF; Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med, 2008, 14, 923-930.
17. Leppik IE: Epilepsy in the elderly. Epilepsia, 2006, 47, Suppl 1, 65-70.
18. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC et al.: CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science, 2003, 302, 84-88.
19. McCarthy MM: Stretching the truth - Why hippocampal neurons are so vulnerable following traumatic brain injury. Exp Neurol, 2003, 184, 40-43.
20. Mechoulam R, Shohami E: Endocannabinoids and traumatic brain injury. Mol Neurobiol, 2007, 36, 68-74.
21. Mehta CR, Hilton JF: Exact power of conditional and unconditional tests: going beyond the 2x2 contingency table. Am Stat, 1993, 47, 91-98.
22. Nagayama T, Sinor AD, Simon RP, Chen J, Graham S, Jin K, Greenberg DA: Cannabinoids and neuroprotection from global and focal cerebral ischemia and in vitro. J Neurosci, 1999, 19, 2987-2995.
23. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 2001, 413, 527-531.
24. Parmentier-Batteur S, Kunlin J, Xiao OM, Lin X, Greenberg DA: Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci, 2002, 22, 9771-9775.
25. Patrylo PR, Tyagi I, Willingham AL, Lee S, Williamson A: Dentate filter function is altered in a proepileptic fashion during aging. Epilepsia, 2007, 48, 1964-1978.
26. Racine RJ: Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephal. Clin Neurophysiol, 1972, 32, 281-294.
27. Rohmel J, Mansmann, U: Unconditional non-asymptotic one-sided tests for independent binomial proportions when the interest lies in showing non-inferiority and/or superiority. Biom J, 1999, 41, 149-170.
28. Shen M, Thayer SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol, 1998, 54, 459-462.
29. Solbrig MV, Adrian R, Baratta J, Piomelli D, Giuffrida A: A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. Exp Neurol, 2005, 194, 355-362.
30. Wettschureck N, van der Stelt M, Tsubokawa H, Krestel H, Moers A, Petrosino S, Schütz G et al.: Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation. Mol Cell Biol, 2006, 26, 5888-5894.
31. Wallace MJ, Blair RE, Falenski KW, Martin BR, De-Lorenzo RJ: The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther, 2003, 307, 129-137.